 |
|
|
| |
Body composition changes on Darunavir/Ritonavir (DRV/r) + either Raltegravir (RAL) or Tenofovir/Emtricitabine (TDF/FTC) as first-line antiretroviral therapy. NEAT 001/ANRS 143. Body composition sub-study
|
| |
| |
Reported by Jules Levin
CROI 2016 Feb 22-24 Boston
Bernardino JI(1), Mocroft A(2), Wallet C(3), Molina JM(4), Knobell H(5), Reynes J(6), Babiker A(7), Raffi F(8), Arribas JR(1) and NEAT 001/ANRS 143 Study Group
(1)Hospital Universitario La Paz. IdiPAZ. Spain; (2)University College London, UK; (3)INSERM U1219, University Bordeaux, France; (4)Hopital Saint-Louis, Paris, France; (5)Hospital del Mar, Barcelona, Spain; (6)Montpellier University Hospital, France; (7)MRC Clinical Trials Unit at UCL, UK; (8)University of Nantes, France.
WEBCAST: http://www.croiwebcasts.org/console/player/29446?mediaType=slideVideo&
LINK TO WEBCAST OF interesting talk, a review of the topic, by Dr Grace Mccomsey on Body Fat, where her discussion includes diet, alcohol, exercise & inflammation.....
http://www.croiwebcasts.org/console/player/29683?mediaType=audio&
|
| |
|
|
|
|
|
